R&D channel feed

La Jol­la whips up some love for iron over­load drug with promis­ing da­ta snap­shot

7 years ago

Pro­tal­ix, Chiesi fire up ac­cel­er­at­ed ap­proval pitch for Fab­ry dis­ease treat­ment

7 years ago

As­traZeneca stocks up on Calquence am­mu­ni­tion for big BTK ri­val­ry with J&J, Ab­b­Vie

7 years ago

In a blow to sci­ence, Trump ad­min­is­tra­tion aborts fed­er­al fund­ing for fe­tal tis­sue re­search

7 years ago

The FDA is forc­ing a small an­tibi­ot­ic play­er back to the clin­ic for a new tri­al — 10 years af­ter first re­jec­tion

7 years ago
FDA+

Take­da suf­fers an­oth­er set­back in its quest to ex­pand myelo­ma drug’s reach — and block­buster po­ten­tial

7 years ago

Mid-stage da­ta on Al­lena's hy­per­ox­aluria drug fu­el op­ti­mism ahead of piv­otal read­out

7 years ago

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

7 years ago
Pharma

Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

7 years ago

Where Te­va failed, Eli Lil­ly gained — mi­graine drug Em­gal­i­ty wins US ap­proval for episod­ic clus­ter headaches

7 years ago

#AS­CO19: MET in­hibitors from In­cyte/No­var­tis and Ger­many's Mer­ck face off for rare sub­set of NSCLC pa­tients

7 years ago

EU stamps his­toric OK on blue­bird’s gene ther­a­py for β-tha­lassemia — now sit back and wait for the price

7 years ago
Cell/Gene Tx

J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

7 years ago

#AS­CO19: Am­gen grows more con­fi­dent in KRAS G12C drug with a pos­i­tive snap­shot for lung can­cer — shares spike

7 years ago

#AS­CO19: Clay Sie­gall is ready to take a big leap for­ward as Seat­tle Ge­net­ics’ next top drug prospect steps on­to cen­ter stage at AS­CO

7 years ago

#AS­CO19 roundup: As­traZeneca, Mer­ck score an­oth­er Lyn­parza hit

7 years ago
Pharma

#AS­CO19: Am­gen shows off their lat­est BC­MA BiTE up­date with plans to hus­tle ahead as ri­vals jos­tle for po­si­tion

7 years ago

#AS­CO19: Strug­gling Nek­tar braves a tough crowd to of­fer up 4 new CRs for skin can­cer drug

7 years ago

#AS­CO19: Sanofi sets the stage for a late ar­rival of their mul­ti­ple myelo­ma drug isat­ux­imab — with J&J and Gen­mab lay­ing in wait

7 years ago

#AS­CO19: Hey Pfiz­er, No­var­tis is go­ing af­ter your block­buster can­cer fran­chise — and they have pos­i­tive OS da­ta

7 years ago
Pharma

#AS­CO19: Mer­ck’s PD-1 star Keytru­da il­lus­trates just how pow­er­ful it can be over 5 years — with plen­ty of room for im­prove­ment

7 years ago
Pharma

Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

7 years ago

Aslan dou­bles down on CSL drug, plots long­shot ri­val­ry with Dupix­ent in atopic der­mati­tis

7 years ago

Io­vance comes back with an­oth­er up­beat can­cer tri­al up­date as #AS­CO19 cur­tain rais­er

7 years ago
First page Previous page 242243244245246247248 Next page Last page
A service from the Financial Times